Search
for

    Sort by

    Research 6

    1. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy JNCI Cancer Spectrum · 2019 · 26 citations
    2. Adverse Hair Reactions to New Targeted Therapies for Cancer Actas Dermo-Sifiliográficas · 2019 · 1 citations
    3. Kalya Research: Complementary and Alternative Medicine (CAM) Virtual Research Assistant from Biomedical Literature 2023
    4. Abstracts from the 17th Congress of the European Society for Dermatology and Psychiatry Acta dermato-venereologica · 2017
    5. Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment Annals of palliative medicine · 2019 · 7 citations
    6. Sacituzumab Govitecan-Hziy (Trodelvy™) Oncology Times · 2021 · 3 citations